The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has recommended ...

Chronic cough is a common but often misdiagnosed symptom, requiring thorough evaluation for underlying respiratory or systemic issues.

In models of chronic cough, the GABAB PAM drug candidate significantly reduced citric acid-induced cough frequency, increased cough latency and showed no signs of tolerance after sub-chronic ...

Adults with refractory chronic cough who received twice-daily camlipixant had decreases in cough frequency and better scores assessing cough severity and cough-related quality of life at day 28 ...

Chronic Refractory Cough Market Outlook 2025-2035: The Chronic Refractory cough market reached a value of USD 9.8 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 14.9 ...

Merck is developing gefapixant, a P2X3 inhibitor, for the treatment of RCC or unexplained chronic cough (UCC) in adults. Neither RCC nor UCC currently has an approved therapy. The FDA, for its part, ...

MILAN -- Twice-daily doses of the oral P2X3 receptor antagonist gefapixant may improve refractory or unexplained chronic cough, but at the cost of adverse events, a meta-analysis and systematic ...

Looking ahead, Satia shared the results of COUGH-1 and COUGH-2, pivotal phase 3 trials evaluating the oral, peripherally acting P2X3-receptor antagonist gefapixant.

The acquisition provides GSK access to Camlipixant, a P2X3 antagonist currently in phase III development for the first-line treatment of adult patients with RCC.

Laval, Quebec-based Bellus aims to treat the coughing condition with camlipixant, a small molecule that blocks P2X3, a receptor associated with the cough mechanism.